Skip to main content

Featured

Weekly Market Snapshot: TSX Rises as Oil Rebounds and U.S. Markets Cool

  TSX Edges Higher on Energy Strength The TSX posted a modest gain this week, supported by rising energy and financial stocks as oil prices rebounded from recent lows. Investor sentiment improved as commodity demand projections stabilized and geopolitical tensions eased. S&P 500 Cools After Strong Run The S&P 500 paused its recent rally, with tech names seeing mild pullbacks as traders reassessed earnings expectations and upcoming Federal Reserve commentary. Defensive sectors saw renewed interest as investors rotated toward value. Oil Rebounds, Supporting Canadian Markets Oil prices climbed on supply concerns and improving global demand forecasts. The rebound helped lift Canadian energy producers and contributed to the TSX’s relative outperformance. Canadian Dollar Holds Steady The CAD traded in a narrow range, balancing stronger commodity prices against softer domestic economic data. Markets continue to watch for Bank of Canada signals on future rate direction. Wi...
Post a Comment
Read more

article

Labels

Alzheimer’s Drug Donanemab Receives FDA Advisers’ Endorsement for Slowing Disease Progression

 

A significant milestone has been reached in the fight against Alzheimer’s disease. Eli Lilly’s closely watched Alzheimer’s drug, donanemab, has won the unanimous backing of federal health advisers. The drug is specifically intended for people with mild dementia caused by this brain-robbing disease.

The decision by the Food and Drug Administration (FDA) advisers comes after careful consideration of the drug’s benefits and risks. Donanemab has demonstrated the ability to modestly slow cognitive decline and memory problems associated with Alzheimer’s. Although it’s not a cure, this endorsement represents a promising step forward in managing the disease.

Here are the key points:

  1. Effectiveness: Donanemab has shown effectiveness in slowing cognitive decline. Patients who received monthly intravenous infusions of the drug declined about 35% more slowly than those who received a placebo.
  2. Risk Assessment: The FDA panel weighed the risks, including side effects like brain swelling and bleeding, which will need monitoring. Despite these risks, the panel concluded that the drug’s benefits outweighed them.
  3. Tau Protein Screening: Unlike previous concerns about tau protein screening, most panelists believed there was enough evidence to prescribe the drug broadly without requiring such screening.
  4. FDA Decision: The FDA will make the final decision on approval later this year. If approved, donanemab would become only the second Alzheimer’s drug in the U.S. shown to convincingly slow cognitive decline.

This endorsement brings hope to individuals and families affected by Alzheimer’s, and we eagerly await the FDA’s final decision. Stay tuned for further updates on this groundbreaking development! 

Labels:

Comments

Post a Comment